Treatment of Multidrug-resistant Pseudomonas aeruginosa Bacteremia in a Immunocompromised Child With Ceftolozane-tazobactam
- Author:
Hyesun YU
1
;
Areum SHIN
;
Doo Ri KIM
;
Jaeyoung CHOI
;
Hee Young JU
;
Joongbum CHO
;
Cheol-In KANG
;
Yae-Jean KIM
Author Information
- Publication Type:Case Report
- From:Pediatric Infection & Vaccine 2023;30(1):47-54
- CountryRepublic of Korea
- Language:English
- Abstract: With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Ceftolozane-tazobactam (Zerbaxa™) is a fifth-generation cephalosporin and beta-lactamase inhibitor that has proved to be effective for treating complicated urinary tract infections and complicated intra-abdominal infections caused by MDR P. aeruginosa. Herein, we report the first case of pediatric hematologic cancer in Korea that was successfully treated for MDR P. aeruginosa bacteremia with Ceftolozane-tazobactam.
